These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22943612)

  • 21. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
    Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
    Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerator MS: its role as a frontline bioanalytical technique.
    Seymour MA
    Bioanalysis; 2011 Dec; 3(24):2817-23. PubMed ID: 22185281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Accelerating clinical insights: how to use accelerator mass spectrometry to make better early development decisions.
    Seymour M
    Altern Lab Anim; 2010 Dec; 38 Suppl 1():15-20. PubMed ID: 21275478
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of 2D chiral chromatography with accelerator mass spectrometry for quantification of (14)C-labeled R- and S-verapamil in plasma.
    Simpson M; Lappin G; Keely BJ
    Bioanalysis; 2010 Mar; 2(3):397-405. PubMed ID: 21083250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Applications of low-abundance-radioisotope measurements with accelerator mass spectrometry to the biomedical sciences].
    Nakamura T
    Tanpakushitsu Kakusan Koso; 1994 Aug; 39(11):2011-20. PubMed ID: 7938599
    [No Abstract]   [Full Text] [Related]  

  • 26. Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers.
    Klem B; Lappin G; Nicholson S; van de Wetering J; de Vries DE; Oosterhuis B; Garner RC
    J Clin Pharmacol; 2006 Apr; 46(4):456-60. PubMed ID: 16554454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory aspects of clinical trials with vaccines.
    Georges AM
    Dev Biol Stand; 1998; 95():69-74. PubMed ID: 9855416
    [No Abstract]   [Full Text] [Related]  

  • 28. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
    Lappin G; Seymour M
    Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [New European rules for clinical trials competition-promoting for Sweden...can we keep the advantage?].
    Strandberg K
    Lakartidningen; 2005 Mar 21-Apr 3; 102(12-13):962-5. PubMed ID: 15887643
    [No Abstract]   [Full Text] [Related]  

  • 30. EU directive on clinical trials penalizes small sponsors.
    Meldolesi A
    Nat Biotechnol; 2003 Aug; 21(8):838. PubMed ID: 12894186
    [No Abstract]   [Full Text] [Related]  

  • 31. Quantitating isotopic molecular labels with accelerator mass spectrometry.
    Vogel JS; Love AH
    Methods Enzymol; 2005; 402():402-22. PubMed ID: 16401517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dating and measurements of radioactive isotopes with accelerator mass spectrometry].
    Nakai N; Nakamura T
    Radioisotopes; 1983 Dec; 32(12):645-55. PubMed ID: 6374773
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of a 250 kV single-stage accelerator mass spectrometer with a 5 MV tandem accelerator mass spectrometer--fitness for purpose in bioanalysis.
    Young GC; Corless S; Felgate CC; Colthup PV
    Rapid Commun Mass Spectrom; 2008 Dec; 22(24):4035-42. PubMed ID: 19009519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Accelerator mass spectrometry best practices for accuracy and precision in bioanalytical (14)C measurements.
    Vogel JS; Giacomo JA; Schulze-König T; Keck BD; Lohstroh P; Dueker S
    Bioanalysis; 2010 Mar; 2(3):455-68. PubMed ID: 21083255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Application of (14)C-accelerator MS in pharmaceutical development.
    Young GC; Seymour M
    Bioanalysis; 2015; 7(5):513-7. PubMed ID: 25826133
    [No Abstract]   [Full Text] [Related]  

  • 36. Maintaining the public trust in clinical research.
    Kelch RP
    N Engl J Med; 2002 Jan; 346(4):285-7. PubMed ID: 11807156
    [No Abstract]   [Full Text] [Related]  

  • 37. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
    Lappin G; Garner RC
    Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Task force ready on financial conflict of interest in research.
    Maloney DM
    Hum Res Rep; 2001 May; 16(5):4. PubMed ID: 11833561
    [No Abstract]   [Full Text] [Related]  

  • 39. Microdose study of 14C-acetaminophen with accelerator mass spectrometry to examine pharmacokinetics of parent drug and metabolites in healthy subjects.
    Tozuka Z; Kusuhara H; Nozawa K; Hamabe Y; Ikushima I; Ikeda T; Sugiyama Y
    Clin Pharmacol Ther; 2010 Dec; 88(6):824-30. PubMed ID: 21048707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measurement implications when developing and implementing interventions.
    Strickland OL
    J Nurs Meas; 2005; 13(3):171-3. PubMed ID: 16605040
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.